Panacea Biotec Limited is an India-based biotechnology company engaged in research and development, manufacturing, sales, distribution, and marketing of pharmaceuticals, vaccines, and biosimilars. Established in 1984 as Panacea Drugs Private Limited and publicly listed in September 1995, the company has grown to become one of the largest vaccine manufacturers and pharmaceutical companies in India, holding the position of India's second-largest vaccine manufacturer.
Panacea Biotec operates through two primary segments: Vaccines and Formulations, with the Vaccines segment generating maximum revenue. The company is a research-based health management firm focused on developing and marketing high-quality, affordable pharmaceutical, vaccine, and herbal products.
The company boasts two manufacturing facilities located in Lalru, Punjab, and Baddi, Himachal Pradesh. Additionally, it maintains two research and development (R&D) centers in Lalru, Punjab, and New Delhi. Its operations extend across various geographies within India, and it actively exports its products to approximately 50 countries worldwide.
Panacea Biotec's diversified portfolio spans across crucial healthcare segments, with a strong focus on vaccines and pharmaceutical formulations.
The company manufactures a comprehensive range of paediatric vaccines marketed in India and internationally. Key products include the hexavalent vaccine, EasySix™; the pentavalent vaccine, Easyfive-TT; and bivalent oral polio vaccine. Other notable products are Easyfour-TT and EasyFourPol.
Panacea Biotec has a history of pioneering innovations in the vaccine space:
- In 2005, it was the first to launch a fully-liquid Pentavalent vaccine (DTwP-HepB-Hib), EasyFive, in India. This vaccine was subsequently pre-qualified by the WHO for introduction in various countries designated by the GAVI vaccination alliance.
- In 2017, the company further innovated by launching the first fully-liquid Hexavalent vaccine (DTwP-HepB-Hib-IPV), EasySix, in India.
The company maintains an impressive pipeline of vaccine candidates, including BPBC, Hepatitis A, Covid-19 VoC mAb, NuVac-23, NuCoVac-11, Td, and DengiAll. It is currently in the process of initiating Phase III clinical trials for NucoVac-11, DengiAll, and Td vaccines.
Panacea Biotec's pharmaceutical product portfolio includes highly innovative prescription products across important therapeutic areas such as pain management, diabetes, cardiovascular, renal disease management, osteoporosis, and gastro-intestinal care. The company has a focused presence in nephrology therapy, specifically in the organ transplantation and dialysis management segments, offering a range of pre-transplant and post-transplant therapies including drugs like lanthanum carbonate, sevelamer, and valganciclovir.
The company also markets several brands in India for the "affordable" treatment of various cancers, including breast cancer, brain tumor, ovarian cancer, pancreatic cancer, prostate cancer, and colorectal cancer. A significant milestone was achieved in 2011 when Panacea Biotec became the first to launch PacliAll, the world's first generic to Abraxane Protein-bound paclitaxel, in India.
Panacea Biotec Ltd demonstrates a dynamic financial landscape, with its market capitalization standing at ₹3,242 crore as of May 23, 2025. The company's stock has seen a 52-week high of ₹581.90 and a 52-week low of ₹112.35.
- Q3 FY25 (December 2024):
- Sales rose 8.63% to ₹163.49 crore compared to ₹150.50 crore in Q3 FY24.
- Net profit reported at ₹4.52 crore, a significant turnaround from a net loss of ₹2.28 crore in Q3 FY24.
- Q1 FY25 (June 2024):
- Sales declined 10.43% to ₹115.72 crore compared to ₹129.19 crore in Q1 FY24.
- Net loss reported at ₹15.88 crore, against a net profit of ₹10.98 crore in Q1 FY24.
- Market Capitalization: ₹3,242 crore (as of May 23, 2025)
- 52-Week High: ₹581.90
- 52-Week Low: ₹112.35
- Promoter Holding (Mar 2025): 72.48%
- Q3 FY25 Sales: ₹163.49 crore
- Q3 FY25 Net Profit/Loss: ₹4.52 crore (Profit)
- Q1 FY25 Sales: ₹115.72 crore
- Q1 FY25 Net Profit/Loss: ₹15.88 crore (Loss)
Panacea Biotec Ltd has actively pursued strategic initiatives to expand its market reach and enhance its product pipeline:
- UNICEF Award: The company received an additional award from UNICEF for the supply of 40 million doses of its bivalent oral polio vaccine (bOPV), valued at approximately US$ 5.20 million (~₹44 crore), to be delivered in Q3 CY2025. The total contract value stands at US$ 14.95 million (approximately ₹127 crore), subject to the signing of requisite amendments to the long-term arrangement, with execution planned for calendar year 2025.
- Adjuvant Commercialization: Panacea Biotec announced the inclusion of its EmulsiPan adjuvant in the CEPI Library, marking its entry into adjuvant commercialization.
- Investment in Subsidiary: Panacea Biotec Pharma (PBCL), a material subsidiary, made a further investment of US$ 925,000 (~₹7.92 crore) in its wholly-owned subsidiary, Panacea Biotec Inc. (PB Inc.), through subscription for 92,500,000 shares of common stock at US$ 0.01 per share.
The promoter holding in Panacea Biotec Ltd has seen a slight decrease, moving from 73.46% as of June 2024 to 72.48% as of March 2025. Rajesh Jain serves as both the Chairman and Managing Director of the company.
Panacea Biotec is strategically positioned within the global vaccine supply chain, benefiting from India's status as a major vaccine manufacturing hub, producing over 60% of the world's vaccines.
- Gavi Adoption: In June 2023, Gavi confirmed the adoption of the wP-hexavalent vaccine, creating a market for over 100 million doses annually by 2030 in Gavi countries, which presents a significant opportunity for Panacea Biotec.
- Indian Private Market Growth: The company is committed to expanding its Indian private market vaccine franchise, with additional launches scheduled within the next 18 to 24 months. It anticipates introducing NucoVacR11 and DengiAllR, among other products, by 2026 to address unmet medical needs, pending successful completion of Phase III clinical trials and receipt of necessary regulatory approvals.
Panacea Biotec's unwavering commitment to innovation and disease prevention through vaccines, combined with its robust manufacturing capabilities and expanding global reach, solidifies its position as a significant player in India's biotechnology sector. With ongoing clinical trials for new vaccines and strategic international partnerships, the company is poised to further strengthen its standing as a leading vaccine manufacturer in India and globally.
